Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$68.62+2.26 (+3.41%)
Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%
Vaxcyte ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vaxcyte's ebitda for the twelve months ending Sep 30, 2026 was -$1.21B. For fiscal 2025 it was -$907.28M. The highest annual figure on record is -$34.50M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$907.28M | – |
| FY2024 | Dec 31, 2024 | -$562.54M | – |
| FY2023 | Dec 31, 2023 | -$464.89M | – |
| FY2022 | Dec 31, 2022 | -$229.42M | – |
| FY2021 | Dec 31, 2021 | -$101.87M | – |
| FY2020 | Dec 31, 2020 | -$88.18M | – |
| FY2019 | Dec 31, 2019 | -$52.92M | – |
| FY2018 | Dec 31, 2018 | -$34.50M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$302.47M | – |
| Q2 FY2026 | Jun 30, 2026 | -$299.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$342.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$266.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$239.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$223.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -$177.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$159.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$138.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$151.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$113.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$195.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$112.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$86.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$70.48M | – |
| Q4 FY2022 | Dec 31, 2022 | -$85.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$57.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$47.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$38.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.12M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.21M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.84M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.93M | – |
See a number that looks wrong?